Sign In
Buy PRAX
$303.39
+21.08 (+7.47%)
At Close: Jun 22, 2026
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
07:00am, Wednesday, 17'th Mar 2021
PRAX-114 Phase 2/3 clinical trial for treatment of MDD to initiate in March 2021 following IND clearance
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
08:00am, Friday, 20'th Nov 2020
CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of the
Praxis Precision Medicines Provides Update On PRAX-114 IND Submission For The Treatment Of Major Depressive Disorder
07:45am, Tuesday, 17'th Nov 2020
- Praxis expects to initiate Phase 2/3 clinical trial for PRAX-114 in MDD in 1H21 -
Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program
08:00pm, Monday, 09'th Nov 2020
CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of the
